As of 2026-04-05, the Intrinsic Value of Hainan Huluwa Pharmaceutical Group Co Ltd (605199.SS) is (7.07) CNY. This 605199.SS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 6.77 CNY, the upside of Hainan Huluwa Pharmaceutical Group Co Ltd is -204.40%.
The range of the Intrinsic Value is (10.89) - (5.73) CNY
Based on its market price of 6.77 CNY and our intrinsic valuation, Hainan Huluwa Pharmaceutical Group Co Ltd (605199.SS) is overvalued by 204.40%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (10.89) - (5.73) | (7.07) | -204.4% |
| DCF (Growth 10y) | (6.31) - (11.72) | (7.72) | -214.0% |
| DCF (EBITDA 5y) | (0.41) - 0.18 | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (0.91) - (0.08) | (1,234.50) | -123450.0% |
| Fair Value | -4.62 - -4.62 | -4.62 | -168.22% |
| P/E | (19.40) - (19.66) | (19.00) | -380.7% |
| EV/EBITDA | (16.21) - 1.41 | (8.00) | -218.2% |
| EPV | (9.55) - (10.91) | (10.23) | -251.1% |
| DDM - Stable | (8.82) - (26.81) | (17.82) | -363.2% |
| DDM - Multi | (1.95) - (4.59) | (2.74) | -140.4% |
| Market Cap (mil) | 2,708.74 |
| Beta | 0.96 |
| Outstanding shares (mil) | 400.11 |
| Enterprise Value (mil) | 3,913.94 |
| Market risk premium | 6.13% |
| Cost of Equity | 9.21% |
| Cost of Debt | 5.00% |
| WACC | 7.56% |